Suicide gene strategies applied in ovarian cancer studies.
Quoc Manh NguyenPierre-François DupréTanguy HauteTristan MontierFrédérique d'ArbonneauPublished in: Cancer gene therapy (2023)
Ovarian cancer represents the most lethal gynecological malignancy among women in developed countries. Despite the recent innovations, the improvements in the 5-year survival rate have been insufficient and the management of this disease still remains a challenge. The fact that the majority of patients experience recurrent or resistant disease have substantiated the necessity of an innovative treatment. Among various strategies investigated, the recent strides made in gene delivery techniques have made gene therapy, including suicide gene strategies, a potential alternative for treating ovarian cancer. Various suicide gene candidates, which are capable of promoting cancer cell apoptosis directly after its entry or indirectly by prodrug administration, can be separated into three systems using enzyme-coding, toxin or pro-apoptotic genes. With this review, we aim to provide an overview of different suicide genes depending on therapeutic strategies, the vectors used to deliver these transgenes specifically to malignant cells, and the combined treatments of these genes with various therapeutic regimens.
Keyphrases
- genome wide identification
- genome wide
- gene therapy
- genome wide analysis
- copy number
- transcription factor
- dna methylation
- end stage renal disease
- ejection fraction
- induced apoptosis
- bioinformatics analysis
- cell death
- escherichia coli
- cell proliferation
- peritoneal dialysis
- polycystic ovary syndrome
- anti inflammatory
- cell cycle arrest
- cancer therapy
- papillary thyroid
- endoplasmic reticulum stress
- pregnant women
- young adults
- squamous cell
- skeletal muscle
- high speed
- free survival
- drug release
- pregnancy outcomes
- patient reported